Green lipped mussel oil complex suppresses lipopolysaccharide stimulated inflammation via regulating nuclear factor-κB and mitogen activated protein kinases signaling in RAW264.7 murine macrophages

다국어 초록 (Multilingual Abstract)

Here we investigated the effect of green lipped mussel oil complex (GLMOC) on inflammation and underlying mechanism in lipopolysaccharide stimulated RAW264.7 murine macrophage cells. GLMOC containing green lipped mussel oil (GLMO), olive oil, and vitamin E (10:20:1) can induce significant suppression of iNOS, leading to reduced nitric oxide synthesis, and cyclooxygenase- 2, leading to reduced prostaglandin E2 synthesis. In addition, it down-regulated the release of pro-inflammatory cytokines, including tumor necrosis factor-a, interleukin (IL)-6, and IL-1b. Similar to upstream signaling mediators, GLMCO inhibited the degradation of inhibitory jB, nuclear translocation of NF-jB, and phosphorylation of mitogen activated protein kinases (MAPKs) in a dose-dependent manner. Among the components of GLMOC, GLMO was responsible for anti-inflammatory efficacy.
Taken together, GLMOC induces anti-inflammatory activity via regulating NF-jB and MAPK signaling in lipopolysaccharide-induced RAW264.7 cells, providing underlying mechanisms that elucidate the anti-inflammatory efficacy of GLMOC.

참고문헌 (Reference)

1 Aktan F., "iNOS-mediated nitric oxide production and its regulation" 75 : 639-653, 2004

2 Emelyanov A, "Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial" 20 : 596-600, 2002

3 Akira S, "Toll-like receptor signalling" 4 : 499-511, 2004

4 Murakami A, "Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals" 121 : 2357-2363, 2007

5 Dumitru CD, "TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway" 103 : 1071-1083, 2000

6 Mitchell S, "Signaling via the NFkappaB system. Wiley Interdiscip" 8 : 227-241, 2016

7 Risbud MV, "Role of cytokines in intervertebral disc degeneration: pain and disc content" 10 : 44-56, 2014

8 Lee CH, "Pain controlling and cytokine-regulating effects of lyprinol, a lipid extract of Perna canaliculus, in a rat adjuvant-induced arthritis model. Evid. Based Complement" 6 : 239-245, 2009

9 Medzhitov R., "Origin and physiological roles of inflammation" 454 : 428-435, 2008

10 Shaw CA, "Nitric oxide and the resolution of inflammation: implications for atherosclerosis" 100 (100): 67-71, 2005

11 Ghosh S, "New regulators of NF-kappaB in inflammation" 8 : 837-848, 2008

12 Mickleborough TD, "Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma" 107 : 1152-1163, 2013

13 Doggrell SA, "Lyprinol-is it a useful anti-inflammatory agent? Evid. Based Complement" 2011 : 307121-, 2011

14 Dugas B., "Lyprinol inhibits LTB4 production by human monocytes" 32 : 284-289, 2000

15 Tenikoff D, "Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease" 40 : 361-365, 2005

16 Murphy KJ, "Lipid, FA, and sterol composition of New Zealand green lipped mussel (Perna canaliculus) and Tasmanian blue mussel (Mytilus edulis)" 37 : 587-595, 2002

17 Hawiger J, "Innate immunity and inflammation: a transcriptional paradigm" 23 : 99-109, 2001

18 Echizen K, "Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and tolllike receptor/MyD88 pathways" 107 : 391-397, 2016

19 Wang D, "Immunosuppression associated with chronic inflammation in the tumor microenvironment" 36 : 1085-1093, 2015

20 Lawson BR, "Immunomodulation of murine collagen-induced arthritis by N,Ndimethylglycine and a preparation of Perna canaliculus" 7 : 20-, 2007

21 Wakimoto T, "Furan fatty acid as an anti-inflammatory component from the green-lipped mussel Perna canaliculus" 108 : 17533-17537, 2011

22 Hielm-Bjorkman A, "Evaluating complementary therapies for canine osteoarthritis part I: Green-lipped mussel (Perna canaliculus)" 6 : 365-373, 2009

23 Gruenwald J, "Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders" 21 : 197-201, 2004

24 Guma M, "Constitutive intestinal NF-kappaB does not trigger destructive inflammation unless accompanied by MAPK activation" 208 : 1889-1900, 2011

25 Cho SH, "Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial" 35 : 212-216, 2003

26 Esteve JB, "COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature" 63 : 385-389, 2005

27 Grienke U, "Bioactive compounds from marine mussels and their effects on human health" 142 : 48-60, 2014

28 Laveti D, "Anti-inflammatory treatments for chronic diseases: a review" 12 : 349-361, 2013

29 Halpern GM, "Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol)" 32 : 272-278, 2000

30 Whitehouse MW, "Anti-inflammatory activity of a lipid fraction (lyprinol) from the NZ green-lipped mussel" 5 : 237-246, 1997

31 McPhee S, "Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, Perna canaliculus" 146 : 346-356, 2007